According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the Phase II clinical trial of injectable sirolimus (albumin binding type) developed independently by the Group to treat patients with progressive or symptomatic epithelioid hemangioendothelioma has officially started at the first center in China.

According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the Phase II clinical trial of injectable sirolimus (albumin binding type) developed independently by the Group to treat patients with progressive or symptomatic epithelioid hemangioendothelioma has officially started at the first center in China.